Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.
Dean F. Bajorin
Consultant or Advisory Role - Dendreon; Lilly; Pfizer
Honoraria - Lilly
Research Funding - Amgen; Dendreon; Genentech; Novartis; Pfizer
Padmanee Sharma
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; Helsinn Therapeutics; Jounce Therapeutics; MedImmune
Seth P. Lerner
Consultant or Advisory Role - Dendreon (U)
Robert Brownell Sims
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Amanda Sanders
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Todd DeVries
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Nadeem A. Sheikh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Leonard G. Gomella
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Research Funding - Dendreon